[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 16 of about 16
1. Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS, An J, Lamperti ED, Koh KP, Ganetzky R, Liu XS, Aravind L, Agarwal S, Maciejewski JP, Rao A: Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature; 2010 Dec 9;468(7325):839-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.
  • The gene encoding TET2 resides at chromosome 4q24, in a region showing recurrent microdeletions and copy-neutral loss of heterozygosity (CN-LOH) in patients with diverse myeloid malignancies.
  • Somatic TET2 mutations are frequently observed in myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), MDS/MPN overlap syndromes including chronic myelomonocytic leukaemia (CMML), acute myeloid leukaemias (AML) and secondary AML (sAML).
  • We show here that TET2 mutations associated with myeloid malignancies compromise catalytic activity.
  • Our results demonstrate that Tet2 is important for normal myelopoiesis, and suggest that disruption of TET2 enzymatic activity favours myeloid tumorigenesis.
  • Measurement of 5hmC levels in myeloid malignancies may prove valuable as a diagnostic and prognostic tool, to tailor therapies and assess responses to anticancer drugs.


2. Cortes J, Giles F, O'Brien S, Thomas D, Albitar M, Rios MB, Talpaz M, Garcia-Manero G, Faderl S, Letvak L, Salvado A, Kantarjian H: Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer; 2003 Jun 1;97(11):2760-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
  • c-kit is expressed in most patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) and PDGF has been implicated in the pathogenesis of myeloproliferative disorders (MPD).
  • Forty-eight patients with AML (n = 10), MDS (n = 8), myelofibrosis (n = 18), atypical chronic myeloid leukemia (CML; n = 7), chronic myelomonocytic leukemia (CMML; n = 3), or polycythemia vera (n = 2) were treated with imatinib 400 mg daily.
  • CONCLUSIONS: Within these small subgroups of disease types, single-agent imatinib did not achieve a significant clinical response among patients with AML, MDS, atypical CML, or CMML without PDGF-R fusion genes.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Myelodysplastic Syndromes / drug therapy. Myeloproliferative Disorders / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Benzamides. Humans. Imatinib Mesylate. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelomonocytic, Chronic / drug therapy. Middle Aged. Polycythemia Vera / drug therapy. Primary Myelofibrosis / drug therapy. Recurrence


3. Diamantidis M, Dimoudis S, Klonizakis P, Badekas K, Koutourli K, Haralambidou-Vranitsa S, Ioannidou-Papagiannaki E: The role of apoptosis and current therapeutic challenges in myelodysplastic syndromes. Hippokratia; 2007 Oct;11(4):178-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clonal nature of MDS places it also at continual risk for transformation to acute leukemia.
  • Predicting overall survival as well as the risk of acute myeloid leukaemia (AML) transformation has been improved by the development of the International Prognostic Scoring System (IPSS).
  • Low-risk patients should be considered for hematopoietic growth factor singly or in combination, while high-risk patients should be offered AML-induction therapy or novel therapeutic agents.
  • Common complications are neutropenias with recurrent infections and red cell transfusion dependence.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Compr Canc Netw. 2006 Jan;4(1):83-90 [16403407.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1188-94 [10666189.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6291-9 [16144933.001]
  • [Cites] Am J Pathol. 2005 Feb;166(2):557-63 [15681838.001]
  • [Cites] N Engl J Med. 1999 May 27;340(21):1649-60 [10341278.001]
  • [Cites] Ann Hematol. 1999 Mar;78(3):125-30 [10211754.001]
  • [Cites] Leuk Res. 1997 May;21(5):415-25 [9225069.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2079-88 [9058730.001]
  • [Cites] Br J Haematol. 1996 Aug;94(2):288-99 [8759889.001]
  • [Cites] Leuk Res. 1996 Mar;20(3):203-19 [8637215.001]
  • [Cites] Br J Haematol. 1995 Jan;89(1):67-71 [7833279.001]
  • [Cites] Br J Haematol. 1992 Oct;82(2):354-7 [1419818.001]
  • [Cites] Leuk Res. 1992;16(3):207-15 [1560670.001]
  • [Cites] Blood. 2004 Jul 15;104(2):579-85 [15039286.001]
  • [Cites] Blood. 2003 Oct 15;102(8):3025-7 [12829603.001]
  • [Cites] Ann Hematol. 2003 Jun;82(6):336-42 [12728337.001]
  • [Cites] Br J Haematol. 2003 Jan;120(2):187-200 [12542475.001]
  • [Cites] Blood. 2003 Feb 1;101(3):1080-6 [12393561.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1615-21 [12200672.001]
  • [Cites] Am J Hematol. 2002 Jun;70(2):115-25 [12111784.001]
  • [Cites] Blood. 2002 Mar 1;99(5):1594-601 [11861273.001]
  • [Cites] Br J Haematol. 2001 Mar;112(3):714-26 [11260077.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3932-8 [11090080.001]
  • [Cites] Br J Haematol. 2000 May;109(2):367-75 [10848827.001]
  • [Cites] J Natl Compr Canc Netw. 2006 Jan;4(1):58-77 [16403405.001]
  • (PMID = 19582190.001).
  • [ISSN] 1790-8019
  • [Journal-full-title] Hippokratia
  • [ISO-abbreviation] Hippokratia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Other-IDs] NLM/ PMC2552980
  • [Keywords] NOTNLM ; acute myeloid leukaemia / apoptosis / myelodysplastic syndromes / prognostic system IPSS / therapeutic strategies
  •  go-up   go-down


Advertisement
4. Lucena-Araujo AR, Panepucci RA, dos Santos GA, Jácomo RH, Santana-Lemos BA, Lima AS, Garcia AB, Araújo AG, Falcão RP, Rego EM: The expression of DeltaNTP73, TATP73 and TP53 genes in acute myeloid leukaemia is associated with recurrent cytogenetic abnormalities and in vitro susceptibility to cytarabine cytotoxicity. Br J Haematol; 2008 Jul;142(1):74-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of DeltaNTP73, TATP73 and TP53 genes in acute myeloid leukaemia is associated with recurrent cytogenetic abnormalities and in vitro susceptibility to cytarabine cytotoxicity.
  • TP73 encodes for two proteins: full-length TAp73 and DeltaNp73, which have little transcriptional activity and exert dominant-negative function towards TP53 and TAp73.
  • We compared TATP73 and DeltaNTP73 expression in acute myeloid leukaemia (AML) samples and normal CD34(+) progenitors.
  • Amongst AML blasts, TATP73 was more expressed in AML harbouring the recurrent genetic abnormalities (RGA): PML-RARA, RUNX1-RUNX1T1 and CBFB-MYH11, whereas higher DeltaNTP73 expression was detected in non-RGA cases.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Cytarabine / therapeutic use. DNA-Binding Proteins / genetics. Genes, p53 / genetics. Leukemia, Myeloid, Acute / genetics. Nuclear Proteins / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Apoptosis / drug effects. Chromosome Aberrations. Drug Resistance, Neoplasm. Gene Expression. Gene Rearrangement. Humans. Polymerase Chain Reaction. Recurrence

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18422993.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Tumor Suppressor Proteins; 04079A1RDZ / Cytarabine
  •  go-up   go-down


5. Tchinda J, Dijkhuizen T, Vlies Pv Pv, Kok K, Horst J: Translocations involving 6p22 in acute myeloid leukaemia at relapse: breakpoint characterization using microarray-based comparative genomic hybridization. Br J Haematol; 2004 Aug;126(4):495-500
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translocations involving 6p22 in acute myeloid leukaemia at relapse: breakpoint characterization using microarray-based comparative genomic hybridization.
  • The detection of chromosomal aberrations is essential for the diagnosis and therapy of acute myeloid leukaemia (AML).
  • We report two cases of de novo AML with translocations involving the breakpoint 6p22 first detected at relapse.
  • At diagnosis, one patient presented a normal karyotype and the other one a trisomy 11 and a del(7)(q31q36).
  • We identified 3q21, a recurrent breakpoint in AML, for the first time as a translocation partner.
  • The occurrence of translocations involving 6p22 after chemotherapy or radiation therapy suggests that one or more therapeutic agents might play a role in their origin.
  • [MeSH-major] Chromosomes, Human, Pair 6 / genetics. Leukemia, Myeloid, Acute / genetics. Translocation, Genetic
  • [MeSH-minor] Chromosomes, Human, Pair 3 / genetics. Female. Humans. Karyotyping. Middle Aged. Nucleic Acid Hybridization. Oligonucleotide Array Sequence Analysis / methods. Recurrence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15287941.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


6. Kessels LW, Visser OJ: [Acute dyspnoea following transfusion of plasma-containing blood products]. Ned Tijdschr Geneeskd; 2005 Feb 12;149(7):369-71
MedlinePlus Health Information. consumer health - Breathing Problems.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute dyspnoea following transfusion of plasma-containing blood products].
  • [Transliterated title] Acute kortademigheid na transfusie van plasmabevattende bloedproducten.
  • A 35-year-old male patient who was given chemotherapy because of chronic myeloid leukaemia became dyspnoeic after transfusion of thrombocytes; initially, no explanation could be found for this dyspnoea.
  • He went home before all diagnostic procedures were evaluated.
  • Chest X-ray revealed bilateral pulmonary oedema, which could be due to transfusion-related acute lung injury (TRALI), especially since there were no indications for a cardiac aetiology.
  • In addition, bioactive compounds produced during the storage of blood products have been implicated.
  • After excluding donors with proven anti-granulocyte antibodies from further donation, there is no increased risk for recurrent episodes after future transfusion of plasma-containing blood products.
  • [MeSH-minor] Acute Disease. Adult. Blood Group Incompatibility. Diuretics / therapeutic use. Humans. Male. Prognosis. Pulmonary Edema / drug therapy. Pulmonary Edema / etiology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ned Tijdschr Geneeskd. 2005 Jul 2;149(27):1540-1; author reply 1541 [16033003.001]
  • (PMID = 15751810.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Diuretics
  •  go-up   go-down


7. Jameel A, Jamil SN: Safety of cytotoxic chemotherapy during pregnancy. J Pak Med Assoc; 2007 Sep;57(9):449-52
MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Six patients (33%) had breast cancer, four (22%) had chronic myeloid leukaemia, two (11%) had Hodgkin's disease, two (11%) had acute myeloid leukaemia and one each had recurrent ovarian carcinoma (5.7%), soft-tissue sarcoma (5.7%), acute lymphoblastic leukaemia (5.7%) and non-Hodgkin's lymphoma (5.7%).
  • Remaining 12/14 (86%) patients gave birth to live, healthy babies and no foetal malformations were observed.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Cytotoxins / adverse effects. Drug-Related Side Effects and Adverse Reactions. Pregnancy Complications. Pregnancy Outcome
  • [MeSH-minor] Adult. Breast Neoplasms / drug therapy. Female. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Neoplasms / drug therapy. Pregnancy. Pregnancy Trimester, Second. Prospective Studies. Time Factors

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18072640.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cytotoxins
  •  go-up   go-down


8. Radsak MP, Salih HR, Sökler M, Kanz L, Denzlinger C: Sustained complete remission of recurrent acute myeloid leukaemia with a single dose of gemtuzumab ozogamicin and low-dose interleukin-2 maintenance. Leukemia; 2002 Sep;16(9):1870-1
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained complete remission of recurrent acute myeloid leukaemia with a single dose of gemtuzumab ozogamicin and low-dose interleukin-2 maintenance.
  • [MeSH-major] Aminoglycosides. Anti-Bacterial Agents / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Immunotoxins / therapeutic use. Interleukin-2 / therapeutic use. Leukemia, Myeloid / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Acute Disease. Aged. Antibodies, Monoclonal, Humanized. Female. Humans. Remission Induction

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12200709.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Anti-Bacterial Agents; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Immunotoxins; 0 / Interleukin-2; 0 / gemtuzumab
  •  go-up   go-down


9. Łuczyński W, Muszyńska-Rosłan K, Krawczuk-Rybak M, Kuźmicz M, Iwaszkiewicz-Pawłowska A, Kaliszewski J: Results of IDA-FLAG programme in the treatment of recurrent acute myeloblastic leukaemia--preliminary report. Med Sci Monit; 2001 Jan-Feb;7(1):125-9
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of IDA-FLAG programme in the treatment of recurrent acute myeloblastic leukaemia--preliminary report.
  • BACKGROUND: Unsatisfactory treatment results of acute myeloblastic leukaemia inspire the search for new drugs, characterised by higher efficiency and lower toxicity.
  • MATERIAL AND METHODS: The assessment of treatment results and undesirable effects was based on the material of 4 children with the relapse of acute myeloblastic leukaemia, after a total of 6 IDA-FLAG protocols.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adolescent. Anemia / chemically induced. Bone Marrow / pathology. Child, Preschool. Cytarabine / administration & dosage. Cytarabine / adverse effects. Disease-Free Survival. Filgrastim. Granulocyte Colony-Stimulating Factor / administration & dosage. Granulocyte Colony-Stimulating Factor / adverse effects. Hematopoietic Stem Cell Transplantation. Humans. Idarubicin / administration & dosage. Idarubicin / adverse effects. Leukopenia / chemically induced. Recombinant Proteins. Recurrence. Thrombocytopenia / chemically induced. Time Factors. Vidarabine / administration & dosage. Vidarabine / adverse effects. Vidarabine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11208507.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Recombinant Proteins; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; FA2DM6879K / Vidarabine; PVI5M0M1GW / Filgrastim; ZRP63D75JW / Idarubicin; Ida-FLAG protocol
  •  go-up   go-down


10. Rao A, Hills RK, Stiller C, Gibson BE, de Graaf SS, Hann IM, O'Marcaigh A, Wheatley K, Webb DK: Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. Br J Haematol; 2006 Mar;132(5):576-83
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials.
  • Down syndrome (DS) children are at an increased risk of developing myelodysplasia and acute myeloid leukaemia (AML).
  • We retrospectively analysed the population-based data on 81 children with myeloid leukaemia of Down syndrome (ML-DS) from the UK National Registry of Childhood Tumours and experience in the Medical Research Council (MRC) AML 10 and AML 12 trials, which enrolled 46 children with ML-DS from 1988 to 2002.
  • Given the increased number of early treatment-related deaths, future treatment protocols should aim to reduce chemotherapy dosage or intensity whilst maintaining low rates of resistant and recurrent disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Down Syndrome / complications. Down Syndrome / drug therapy. Leukemia, Myeloid / complications. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Adolescent. Amsacrine / administration & dosage. Child. Child, Preschool. Cytarabine / administration & dosage. Cytogenetic Analysis. Daunorubicin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Infant. Leukocyte Count. Male. Mitoxantrone / administration & dosage. Thioguanine / administration & dosage. Treatment Outcome. United Kingdom

  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. THIOGUANINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. AMSACRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445830.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0300133
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 00DPD30SOY / Amsacrine; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone; FTK8U1GZNX / Thioguanine; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


11. Bahng H, Lee JH, Ahn JH, Lee JH, Lee JS, Kim SH, Kim WK, Lee KH: Combination chemotherapy utilizing continuous infusion of intermediate-dose cytarabine for refractory or recurrent acute myeloid leukemia. Leuk Res; 2001 Mar;25(3):213-6
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy utilizing continuous infusion of intermediate-dose cytarabine for refractory or recurrent acute myeloid leukemia.
  • Between October 1991 and December 1998, 19 patients (12 males and 7 females) with refractory (six patients) or recurrent (13 patients) AML were treated with a combination chemotherapy of cytarabine given by continuous infusion over 24-h at a rate of 1 upward arrow g/m2 per day for 5 days along with idarubicin (12 upward arrow mg/m2 per day x 3) and etoposide (150 mg /m(2) per day x 3).
  • Further studies are necessary to elucidate optimum dose and schedule of cytarabine in a setting of refractory or relapsed acute myeloid leukemia (AML).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cytarabine / administration & dosage. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Actuarial Analysis. Acute Disease. Adolescent. Adult. Drug Resistance, Neoplasm. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Recurrence. Remission Induction. Salvage Therapy. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11226516.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine
  •  go-up   go-down


12. Aschoff P, Häntschel M, Oksüz M, Werner MK, Lichy M, Vogel W, Pfannenberg C: Integrated FDG-PET/CT for detection, therapy monitoring and follow-up of granulocytic sarcoma. Initial results. Nuklearmedizin; 2009;48(5):185-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: Granulocytic sarcomas (GS) are rare extramedullary manifestations of myeloid or lymphoblastic leukaemia.
  • RESULTS: 52 untreated or recurrent GS lesions were detected by FDG-PET/CT and all showed an increased FDG uptake with a mean SUVmax and SUVavg of 5.1 and 3.4, respectively.
  • PET/CT identified recurrent GS in 3 patients.
  • Therefore, FDG-PET/CT appears to be a promising diagnostic and monitoring tool in the management of patients with GS.
  • [MeSH-major] Sarcoma, Myeloid / radionuclide imaging
  • [MeSH-minor] Adult. Female. Fluorodeoxyglucose F18. Follow-Up Studies. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / radiography. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / radionuclide imaging. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / radiography. Leukemia, Myeloid, Acute / radionuclide imaging. Male. Middle Aged. Neoplasm Staging. Positron-Emission Tomography. Retrospective Studies. Tomography, X-Ray Computed. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19710955.001).
  • [ISSN] 0029-5566
  • [Journal-full-title] Nuklearmedizin. Nuclear medicine
  • [ISO-abbreviation] Nuklearmedizin
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


13. Cornely OA, Böhme A, Reichert D, Reuter S, Maschmeyer G, Maertens J, Buchheidt D, Paluszewska M, Arenz D, Bethe U, Effelsberg J, Lövenich H, Sieniawski M, Haas A, Einsele H, Eimermacher H, Martino R, Silling G, Hahn M, Wacker S, Ullmann AJ, Karthaus M, Multinational Case Registry of the Infectious Diseases Working Party of the German Society for Hematology and Oncology: Risk factors for breakthrough invasive fungal infection during secondary prophylaxis. J Antimicrob Chemother; 2008 Apr;61(4):939-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During leukaemia induction chemotherapy, IFI often prohibited further curative treatment, thus predisposing for leukaemia relapse.
  • Secondary prophylaxis of IFI is widely administered, but reliable data on outcome and risk factors for recurrent IFI during subsequent chemotherapy are not available.
  • This study determines risk factors for recurrent IFI in leukaemia patients.
  • METHODS: From 25 European cancer centres, 166 consecutive patients with acute myelogenous leukaemia (AML) and a recent history of proven or probable pulmonary IFI were included.
  • Recurrent IFI occurred in 26 patients (15.7%).
  • Usage of high efficiency particulate air filter appeared protective (OR 0.198, CI 0.036-1.089).
  • CONCLUSIONS: Duration of neutropenia, high-dose cytarabine, prior antibiotic therapy and a partial response to the first IFI therapy were risk factors for recurrent IFI and should be considered in AML patients with prior pulmonary IFI undergoing further chemotherapy.
  • [MeSH-major] Antifungal Agents / therapeutic use. Mycoses / epidemiology. Mycoses / prevention & control
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemoprevention. Child. Child, Preschool. Female. Humans. Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / drug therapy. Logistic Models. Male. Middle Aged. Recurrence. Risk Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18272515.001).
  • [ISSN] 1460-2091
  • [Journal-full-title] The Journal of antimicrobial chemotherapy
  • [ISO-abbreviation] J. Antimicrob. Chemother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents
  •  go-up   go-down


14. Adler H, Widmer A, Frei R: Emergence of a teicoplanin-resistant small colony variant of Staphylococcus epidermidis during vancomycin therapy. Eur J Clin Microbiol Infect Dis; 2003 Dec;22(12):746-8
Hazardous Substances Data Bank. Vancomycin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Small colony variants of Staphylococcus aureus can cause persistent and recurrent infections.
  • The small colony variant was isolated from blood cultures of a patient with acute leukaemia and therapy-induced neutropenia who was treated with vancomycin for catheter-associated bloodstream infection.
  • [MeSH-major] Staphylococcal Infections / diagnosis. Staphylococcal Infections / drug therapy. Staphylococcus epidermidis / isolation & purification. Teicoplanin / pharmacology. Vancomycin / therapeutic use
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blood / microbiology. Disease Progression. Drug Resistance, Bacterial. Fatal Outcome. Humans. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / drug therapy. Male. Microbial Sensitivity Tests. Neutropenia / drug therapy. Neutropenia / etiology. Risk Assessment. Treatment Failure

  • MedlinePlus Health Information. consumer health - Staphylococcal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rev Infect Dis. 1987 Nov-Dec;9(6):1168-74 [3423588.001]
  • [Cites] J Clin Microbiol. 2000 Jun;38(6):2051-4 [10834952.001]
  • [Cites] J Clin Microbiol. 1998 Jul;36(7):1853-8 [9650924.001]
  • [Cites] Clin Infect Dis. 1998 Aug;27 Suppl 1:S68-74 [9710673.001]
  • [Cites] J Clin Microbiol. 1996 Jul;34(7):1765-8 [8784585.001]
  • [Cites] J Clin Microbiol. 1990 Apr;28(4):676-9 [2332465.001]
  • [Cites] Clin Infect Dis. 1999 Oct;29(4):932-4 [10589914.001]
  • [Cites] N Engl J Med. 1977 Jun 9;296(23):1305-9 [323710.001]
  • [Cites] J Antimicrob Chemother. 2001 Feb;47(2):163-70 [11157900.001]
  • [Cites] N Engl J Med. 1987 Apr 9;316(15):927-31 [3821839.001]
  • [Cites] J Clin Microbiol. 2001 Jul;39(7):2439-44 [11427551.001]
  • [Cites] Clin Infect Dis. 1997 Nov;25(5):1250-1 [9402396.001]
  • [Cites] J Infect Dis. 1998 Apr;177(4):1023-9 [9534977.001]
  • [Cites] Clin Infect Dis. 1995 Jan;20(1):95-102 [7727677.001]
  • (PMID = 14605939.001).
  • [ISSN] 0934-9723
  • [Journal-full-title] European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
  • [ISO-abbreviation] Eur. J. Clin. Microbiol. Infect. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 61036-62-2 / Teicoplanin; 6Q205EH1VU / Vancomycin
  •  go-up   go-down


15. Hänel M, Thiede C, Helwig A, Prange-Krex G, Babatz J, Haack M, Kroschinsky F, Fetscher S, Ehninger G, Bornhäuser M: Successful combination of anti-CD33 antibody (gemtuzumab ozogamicin) and minimal conditioning before second allografting in recurrent acute myeloid leukaemia. Br J Haematol; 2003 Mar;120(6):1093-4
MedlinePlus Health Information. consumer health - Antibiotics.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful combination of anti-CD33 antibody (gemtuzumab ozogamicin) and minimal conditioning before second allografting in recurrent acute myeloid leukaemia.
  • [MeSH-major] Aminoglycosides. Anti-Bacterial Agents / therapeutic use. Antibodies, Monoclonal / therapeutic use. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid / drug therapy. Transplantation Conditioning
  • [MeSH-minor] Acute Disease. Adult. Antibodies, Monoclonal, Humanized. Female. Humans. Reoperation. Transplantation, Homologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12648086.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Anti-Bacterial Agents; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / gemtuzumab
  •  go-up   go-down


16. Mailänder V, Scheibenbogen C, Thiel E, Letsch A, Blau IW, Keilholz U: Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia; 2004 Jan;18(1):165-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Leukemia, Myeloid / prevention & control. Neoplasm Recurrence, Local / prevention & control. Vaccination. WT1 Proteins / immunology
  • [MeSH-minor] Acute Disease. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Drug Resistance, Neoplasm. Female. Hematologic Diseases / prevention & control. Humans. Peptide Fragments / immunology. Remission Induction. Renal Insufficiency / prevention & control

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Immunization.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14603333.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Peptide Fragments; 0 / WT1 Proteins
  •  go-up   go-down






Advertisement